Trinity Intelligence Newsletter | November 2025
This month, we announced Scott Evangelista as Trinity’s new CEO. His unique experience—as a board advisor, global executive, and industry leader—makes him ideally suited to lead Trinity into its next chapter of growth, powering the future of life sciences commercialization.
We also opened registration for a panel webinar discussing AI predictions for 2026, featuring experts from Trinity, Snowflake and Tris Pharma.
This edition of the newsletter also includes:
- A white paper highlighting a better way forward for point-of-care (POC) measurement
- An advisory brief examining the role of commercial insights across the drug development lifecycle
- The fifth annual Digital Marketing Competency Report
- A blog examining trends reshaping interventional cardiology
⭐️Featured Webinar
Will AI Redefine Life Sciences? 2026 Predictions
🕑 December 11, 2025 | 2:00 – 2:45 PM ET
Additional sessions for EU and APAC
Join us for a forward-looking panel discussion featuring experts from Trinity, Snowflake, and Tris Pharma. This panel brings together real-world expertise and operational insights to examine the AI trends set to shape the future of life sciences commercialization.
As 2025 nears its end, the pace of change continues to accelerate across complex, regulated industries. With quality data and real-world healthcare decision-making as its foundation, domain-driven AI is giving organizations a decisive advantage. Whether you’re considering your first AI initiative or scaling existing efforts, this session will spark new ideas and partnerships.
💡 White Paper
Unlocking Point of Care Marketing’s True Impact with Patient‑Centric Measurement
An industry research collaboration between Point of Care Marketing Association, Trinity Life Sciences, Syneractiv and MedFuse.
Point of Care marketing now represents over $1 billion in annual U.S. healthcare advertising spend—yet most Marketing Mix Models (MMM) are measuring it wrong. The culprit? Binary “on/off” indicators that treat a small practice seeing 65 patients per day the same as a large practice seeing 250+. This oversimplification creates systematic bias: high-traffic environments are dramatically undervalued while low-traffic ones are overvalued, leading to misallocated budgets and eroded confidence in POC as a channel.
Our case study shows a better way forward for POC measurement.
❗️Read Now
Recommended by LinkedIn
🔍 Advisory Brief
The Role of Commercial Input Across the Drug Development Lifecycle
R&D and clinical functions take precedence in early planning, often delaying commercial involvement. This leads to missed opportunities to influence target product profile (TPP) design, trial endpoints, and payer strategy, resulting in suboptimal TPPs, overlooked market needs, and slower uptake post-launch.
The aim of this paper is to define when commercial input matters most, and what level of rigor is appropriate by development stage
❗️Read Now
📱Excerpt
Fifth Annual Digital Marketing Competency Report
Trinity is pleased to announce the release of its 5th Annual TGaS Digital Marketing Competency Report, a comprehensive analysis benchmarking digital maturity and omnichannel innovation across more than 150 biopharma brands. This new edition, a three-part series, spotlights the continued transformation of digital engagement in life sciences and sets the standard for patient and caregiver connection in today’s digital-first landscape.
Click the link below to download a summary of the report, including a ranking of all 150+ biopharma brands.
❗️Read Now
❗️Blog
Catalysts of Change: Four Innovations Redefining Interventional Cardiology
Interventional cardiology continues to advance toward precision-based care, where treatment strategies are matched to patient characteristics and real-world outcomes guide decision-making. Coming out of TCT 2025, one of the leading interventional cardiology conferences, Trinity sees four trends shaping the next 2-3 years in the interventional cardiology market.
❗️Read Now